Table 2.
Clinical outcome measures.
| Time point | Responders (n = 19) | Non-responders (n = 22) | P | |
|---|---|---|---|---|
| Difference from baseline in days of migraine (SD) | Week 4 | 4.8 (3.7) | 0.5 (2.6) | 8.253 × 10−5a |
| Visual analog scale (SD) |
Baseline | 7.7 (1.6) | 7.2 (1.5) | 1.106 × 10−4c |
| Week 4 | 4.0 (2.9)*** | 6.6 (1.6)# | ||
| Number of people with acute medication, n (%) |
Baseline | 6 (31.6) | 9 (40.9) | 0.536b |
| Week 4 | 6 (31.6) | 9 (40.9) | 0.536b |
Data were presented as mean ± standard deviation (SD), number (percentage).
a
P-values based on the independent two sample t-test.
b
P-values based on the chi-squared test.
c
P-values based on repeated measurement analysis of variance.
***
P < 0.001 for the post-hoc comparison of pre- vs. post-treatment values in responders.
#
P < 0.05, for the post-hoc comparison of responders vs. non-responders in post-treatment values.